Research Analysts Set Expectations for DNTH FY2025 Earnings

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) – Equities researchers at HC Wainwright boosted their FY2025 earnings per share estimates for Dianthus Therapeutics in a research report issued on Monday, November 10th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($3.18) per share for the year, up from their prior estimate of ($3.88). HC Wainwright has a “Buy” rating and a $47.00 price target on the stock. The consensus estimate for Dianthus Therapeutics’ current full-year earnings is ($2.61) per share. HC Wainwright also issued estimates for Dianthus Therapeutics’ Q4 2025 earnings at ($0.89) EPS, Q1 2026 earnings at ($0.92) EPS, Q2 2026 earnings at ($0.95) EPS, Q3 2026 earnings at ($0.99) EPS, Q4 2026 earnings at ($1.02) EPS, FY2026 earnings at ($3.87) EPS, FY2027 earnings at ($4.07) EPS, FY2028 earnings at ($4.67) EPS and FY2029 earnings at ($2.70) EPS.

A number of other analysts have also recently commented on DNTH. Stifel Nicolaus upped their target price on shares of Dianthus Therapeutics from $52.00 to $65.00 and gave the company a “buy” rating in a report on Friday, September 12th. Raymond James Financial reissued an “outperform” rating and set a $63.00 price objective (up previously from $56.00) on shares of Dianthus Therapeutics in a research report on Tuesday, September 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Wednesday, October 8th. Wedbush lifted their target price on Dianthus Therapeutics from $44.00 to $46.00 and gave the company an “outperform” rating in a research report on Thursday, November 6th. Finally, Guggenheim boosted their price target on Dianthus Therapeutics from $92.00 to $100.00 and gave the company a “buy” rating in a report on Tuesday, September 9th. Nine analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $63.43.

Dianthus Therapeutics Stock Up 7.3%

Shares of NASDAQ:DNTH opened at $38.72 on Wednesday. The stock has a market capitalization of $1.25 billion, a PE ratio of -11.13 and a beta of 1.56. The firm’s 50 day moving average price is $35.44 and its 200-day moving average price is $25.41. Dianthus Therapeutics has a twelve month low of $13.36 and a twelve month high of $40.16.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its earnings results on Wednesday, November 5th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.11). Dianthus Therapeutics had a negative return on equity of 33.02% and a negative net margin of 4,106.04%.The firm had revenue of $0.40 million during the quarter, compared to analysts’ expectations of $0.58 million.

Insider Activity at Dianthus Therapeutics

In other news, CFO Ryan Savitz sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, September 9th. The stock was sold at an average price of $35.00, for a total transaction of $700,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 8.15% of the stock is owned by company insiders.

Institutional Investors Weigh In On Dianthus Therapeutics

A number of hedge funds have recently made changes to their positions in DNTH. Raymond James Financial Inc. purchased a new position in Dianthus Therapeutics during the 2nd quarter valued at approximately $27,000. US Bancorp DE boosted its position in shares of Dianthus Therapeutics by 2,013.3% during the 1st quarter. US Bancorp DE now owns 1,585 shares of the company’s stock valued at $29,000 after acquiring an additional 1,510 shares during the last quarter. Parkside Financial Bank & Trust grew its holdings in shares of Dianthus Therapeutics by 131.7% in the third quarter. Parkside Financial Bank & Trust now owns 950 shares of the company’s stock valued at $37,000 after purchasing an additional 540 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of Dianthus Therapeutics by 330.7% in the second quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock valued at $80,000 after purchasing an additional 3,317 shares in the last quarter. Finally, AlphaQuest LLC bought a new stake in Dianthus Therapeutics in the second quarter worth $94,000. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.